Pliant Therapeutics, Inc. (PLRX)
NMS · Healthcare · Biotechnology
$1.05
-1.87%
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
Market Cap
$65.0M
Shares Outstanding
61.9M
Exchange
NMS
Currency
USD
About Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -45.6M | -28.3M | -23.6M | -21.8M |
| Net Income | -43.3M | -26.3M | -23.6M | -20.0M |
| Diluted EPS | $-0.71 | $-0.43 | $-0.38 | $-0.32 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 9.7M | 1.6M | 0.00 | 0.00 |
| Operating Income | -127.2M | -184.1M | -228.4M | -156.4M |
| Net Income | -123.3M | -161.3M | -210.3M | -149.3M |
| Diluted EPS | $-2.94 | $-2.75 | $-3.47 | $-2.43 |